Apellis Pharmaceuticals
APLSApprovedApellis Pharmaceuticals is a commercial-stage biopharma company focused on developing first-in-class therapies by targeting C3, the central protein of the complement system. The company has successfully brought two medicines to market—SYFOVRE® (pegcetacoplan) for geographic atrophy and EMPAVELI® (pegcetacoplan) for PNH—addressing significant unmet needs in ophthalmology and hematology. With a deep pipeline exploring C3 inhibition across rare, retinal, and neurological diseases, Apellis leverages over two decades of complement expertise to pursue life-changing treatments. The company operates with a culture of courageous science and compassion, driven by its founding scientific team.
APLS · Stock Price
Historical price data
AI Company Overview
Apellis Pharmaceuticals is a commercial-stage biopharma company focused on developing first-in-class therapies by targeting C3, the central protein of the complement system. The company has successfully brought two medicines to market—SYFOVRE® (pegcetacoplan) for geographic atrophy and EMPAVELI® (pegcetacoplan) for PNH—addressing significant unmet needs in ophthalmology and hematology. With a deep pipeline exploring C3 inhibition across rare, retinal, and neurological diseases, Apellis leverages over two decades of complement expertise to pursue life-changing treatments. The company operates with a culture of courageous science and compassion, driven by its founding scientific team.
Technology Platform
Targeted C3 therapy platform designed to comprehensively control the complement cascade by inhibiting the central protein C3, which addresses all three pathways of complement activation.
Pipeline Snapshot
2727 drugs in pipeline, 11 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| APL-2 + APL-2 | Geographic Atrophy | Phase 3 | |
| Pegcetacoplan | C3G | Phase 3 | |
| APL-2 + APL-2 | Geographic Atrophy | Phase 3 | |
| APL-2, Pegcetacoplan | Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | |
| APL-2 | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 |
FDA Approved Drugs
2Opportunities
Risk Factors
Competitive Landscape
Apellis faces competition from Astellas/Iveric Bio's IZERVAY in GA and from Alexion/AstraZeneca's Soliris/Ultomiris and Novartis's Fabhalta in PNH. Its differentiation is based on its first-in-class C3 inhibition platform, which offers a broader mechanism of action targeting the central node of the complement cascade.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile